HR 2554 · in committee · significant
Lower Drug Costs for Families Act
- healthcare
What this bill does
- The bill requires drug manufacturers to issue rebates on brand-name prescription drugs sold through private insurance.
- Patients with private health insurance and pharmaceutical manufacturers are affected by the rebate requirements.
- Manufacturers face civil penalties for non-compliance; rebate calculations are indexed to 2016 drug prices.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might drug manufacturers adjust their pricing strategies if required to issue rebates indexed to 2016 prices rather than current market rates?
- 02
Who ultimately bears the cost of manufacturer rebates—patients, insurers, employers, or some combination—and how does that affect insurance premiums?
- 03
What evidence suggests that rebate requirements will reduce out-of-pocket costs for patients with private insurance compared to other policy approaches?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-NV-4
Steven Horsford
Citizen cosponsors
0
In Congress
2/ 435
House Reps cosponsoring
Introduced 2025-04-01
Joining the bill
Legislative timeline
2025-04-01 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-04-01 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-04-01 · IntroReferral
Introduced in House
2025-04-01 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.